Superworth

Atara Biotherapeutics revenue ATRA

Sales by quarter and over the last twelve months, from 2022.

Last 12 months, to Dec 31, 2024
$128.9M
Latest quarter, Q4 FY24
$32.8M
+670% on a year earlier
Fiscal year 2024
$128.9M
+1404% on the year before

Atara Biotherapeutics' revenue was $128.9M over the twelve months to Dec 31, 2024, up 1404% on a year earlier.

In its latest quarter, Q4 FY24, it was $32.8M, up 670% on the same quarter a year before.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2024$128.9M+1404%
FY2023$8.6M−87%
FY2022$63.6Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q4 FY24$32.8M+670%$128.9M
Q3 FY24$40.2M+1780%$100.4M
Q2 FY24$28.6M+2893%$62.4M
Q1 FY24$27.4M+2131%$34.7M
Q4 FY23$4.3M+1824%$8.6M
Q3 FY23$2.1M−52%$4.5M
Q2 FY23$957K−98%$6.9M
Q1 FY23$1.2M−83%$57.5M
Q4 FY22$221Kn/a$63.6M
Q3 FY22$4.5Mn/an/a
Q2 FY22$51.6Mn/an/a
Q1 FY22$7.3Mn/an/a

Against its peers

Companies in Healthcare nearest Atara Biotherapeutics' size, closest first, today.

CompanyRevenue, 12 monthsGrowth
ATRAAtara Biotherapeuticsn/m
ICCCImmucell$30.7M+8% a year
KEQUKewaunee Scientific$277.2M+5% a year
LFVNLifevantage$182.6M−20% a year
SPROSpero Therapeutics$47M−3% a year
APTAlpha Pro Tech$61.9M+6% a year
ATNMActinium Pharmaceuticalsn/m
NEPHNephros$20.7M+24% a year
PDEXPro DEX$77.5M+16% a year
PLXProtalix BioTherapeutics$80.6M+30% a year
NATRNatures Sunshine Products$492M+7% a year
Peer median$77.5M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Atara Biotherapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.